What is Sinopharm Group Co Return-on-Tangible-Equity?
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sinopharm Group Co's annualized net income for the quarter that ended in Dec. 2024 was HK$7,144 Mil. Sinopharm Group Co's average shareholder tangible equity for the quarter that ended in Dec. 2024 was HK$71,468 Mil. Therefore, Sinopharm Group Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2024 was 10.00%.
The historical rank and industry rank for Sinopharm Group Co's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:01099'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.68 Med: 17.03 Max: 20.2
Current: 10.73
During the past 13 years, Sinopharm Group Co's highest Return-on-Tangible-Equity was 20.20%. The lowest was 10.68%. And the median was 17.03%.
HKSE:01099's Return-on-Tangible-Equity is ranked better than 61.11% of 108
companies
in the Medical Distribution industry
Industry Median: 8.555
vs HKSE:01099: 10.73
Sinopharm Group Co Return-on-Tangible-Equity Historical Data
The historical data trend for Sinopharm Group Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Sinopharm Group Co Return-on-Tangible-Equity Chart
Competitive Comparison of Sinopharm Group Co's Return-on-Tangible-Equity
For the Medical Distribution subindustry, Sinopharm Group Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co's Return-on-Tangible-Equity Distribution in the Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2024) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Sinopharm Group Co (HKSE:01099) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sinopharm Group Co Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Sinopharm Group Co's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01099 has been successfully added to your 